JP2021517893A5 - - Google Patents

Info

Publication number
JP2021517893A5
JP2021517893A5 JP2020548735A JP2020548735A JP2021517893A5 JP 2021517893 A5 JP2021517893 A5 JP 2021517893A5 JP 2020548735 A JP2020548735 A JP 2020548735A JP 2020548735 A JP2020548735 A JP 2020548735A JP 2021517893 A5 JP2021517893 A5 JP 2021517893A5
Authority
JP
Japan
Prior art keywords
methyl
pyridine
carboxamide
fluoroimidazo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517893A (ja
JP7590183B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021897 external-priority patent/WO2019178129A1/en
Publication of JP2021517893A publication Critical patent/JP2021517893A/ja
Publication of JP2021517893A5 publication Critical patent/JP2021517893A5/ja
Priority to JP2023200830A priority Critical patent/JP2024012697A/ja
Application granted granted Critical
Publication of JP7590183B2 publication Critical patent/JP7590183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548735A 2018-03-13 2019-03-12 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用 Active JP7590183B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023200830A JP2024012697A (ja) 2018-03-13 2023-11-28 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862642376P 2018-03-13 2018-03-13
US62/642,376 2018-03-13
US201862757728P 2018-11-08 2018-11-08
US62/757,728 2018-11-08
PCT/US2019/021897 WO2019178129A1 (en) 2018-03-13 2019-03-12 Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023200830A Division JP2024012697A (ja) 2018-03-13 2023-11-28 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用

Publications (3)

Publication Number Publication Date
JP2021517893A JP2021517893A (ja) 2021-07-29
JP2021517893A5 true JP2021517893A5 (enExample) 2022-03-22
JP7590183B2 JP7590183B2 (ja) 2024-11-26

Family

ID=65904618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548735A Active JP7590183B2 (ja) 2018-03-13 2019-03-12 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
JP2023200830A Withdrawn JP2024012697A (ja) 2018-03-13 2023-11-28 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023200830A Withdrawn JP2024012697A (ja) 2018-03-13 2023-11-28 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用

Country Status (9)

Country Link
US (3) US10730874B2 (enExample)
EP (1) EP3765459A1 (enExample)
JP (2) JP7590183B2 (enExample)
KR (1) KR20200143376A (enExample)
CN (1) CN112135825A (enExample)
AU (1) AU2019234670B2 (enExample)
CA (1) CA3093802A1 (enExample)
TW (1) TWI834641B (enExample)
WO (1) WO2019178129A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028362A1 (en) 2017-08-04 2019-02-07 Dyax Corp. INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
TW202045011A (zh) * 2019-02-28 2020-12-16 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
KR20210145788A (ko) 2019-04-01 2021-12-02 닛산 가가쿠 가부시키가이샤 피리다지논 화합물 및 제초제
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
WO2021211938A1 (en) 2020-04-17 2021-10-21 Shire Human Genetic Therapies, Inc. Solid forms of inhibitors of plasma kallikrein
EP4623913A3 (en) 2020-04-17 2025-12-24 Takeda Pharmaceutical Company Limited Forms and compositions of inhibitors of plasma kallikrein
WO2022071428A1 (ja) 2020-09-30 2022-04-07 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
US20240199613A1 (en) 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
CN117396474A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂
JP2024512497A (ja) * 2021-03-17 2024-03-19 武田薬品工業株式会社 血漿カリクレインの阻害剤
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂
BR112023018619A2 (pt) * 2021-03-17 2023-11-28 Takeda Pharmaceuticals Co Inibidores de heteroaril de calicreína plasmática
EP4587434A1 (en) 2022-09-15 2025-07-23 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
TW202500130A (zh) * 2023-05-09 2025-01-01 美商安進公司 用作15-前列腺素脫氫酶調節劑之5,6-稠合和6,6-稠合的雙環醇和醚及組成物
CN119708015A (zh) * 2023-09-28 2025-03-28 杭州圣域生物医药科技有限公司 杂芳基化合物、其中间体、制备方法和应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPH0832707B2 (ja) 1986-02-05 1996-03-29 富山化学工業株式会社 新規なセフアロスポリン類およびその塩
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1992020350A1 (en) 1991-05-20 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000256286A (ja) 1999-03-11 2000-09-19 Kaken Pharmaceut Co Ltd アルキルアミン誘導体
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2531512A1 (en) 2003-07-09 2005-01-20 Paradigm Therapeutics Ltd. Organosilicon compounds and their use
EP1758579A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US20090118296A1 (en) 2005-07-20 2009-05-07 Merck Frosst Canada Ltd. Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 c-Met의 억제제 및 이의 용도
PL1981519T3 (pl) * 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
WO2008016883A2 (en) * 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP1908762A2 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
KR100994115B1 (ko) 2008-08-18 2010-11-15 삼성모바일디스플레이주식회사 광효율 개선층을 구비한 유기 발광 소자
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2010137738A1 (en) 2009-05-28 2010-12-02 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of stress-related conditions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
JP2012111731A (ja) 2010-11-26 2012-06-14 Otsuka Pharmaceut Co Ltd 医薬
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013052526A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
WO2013081094A1 (ja) 2011-11-30 2013-06-06 東レ株式会社 イミダゾ[1,2-a]ピリジン誘導体及びその医薬用途
KR102057351B1 (ko) 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
US9822129B2 (en) 2012-03-02 2017-11-21 Genentech, Inc. Amido spirocyclic amide and sulfonamide derivatives
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はahi1の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
EP3063150B1 (de) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
EP3087067B1 (en) 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
US9611252B2 (en) * 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CA2935683A1 (en) * 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2015188051A1 (en) 2014-06-06 2015-12-10 Biogen Ma Inc. Atx modulating agents
AU2015289643B2 (en) * 2014-07-16 2020-10-22 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CN105777632A (zh) 2015-01-09 2016-07-20 成都贝斯凯瑞生物科技有限公司 芳环并氮杂环衍生物及其应用
ES2735924T3 (es) 2015-04-17 2019-12-20 Dow Agrosciences Llc Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procesos, relacionados con ellas
US10981893B2 (en) 2015-07-01 2021-04-20 Attune Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CA2991174A1 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2016367261A1 (en) 2015-12-11 2018-07-26 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN110022875A (zh) 2016-07-11 2019-07-16 莱福斯希医药公司 治疗性抑制化合物
US20190292155A1 (en) 2016-07-15 2019-09-26 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018064510A1 (en) * 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US11111245B2 (en) 2017-02-01 2021-09-07 Aucentra Therapeutics Pty Ltd Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
AU2018244935A1 (en) 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1
WO2018229543A2 (en) 2017-06-14 2018-12-20 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
WO2019028362A1 (en) 2017-08-04 2019-02-07 Dyax Corp. INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
TW202116753A (zh) 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 以噌啉作為hpk1的抑制劑
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
DK4031547T3 (da) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co Plasmakallikreininhibitorer og anvendelser deraf
CN114573575B (zh) 2020-04-28 2023-08-04 江南大学 一类含氧五元杂环化合物、合成方法、药物组合物及用途
US20240199612A1 (en) 2021-02-23 2024-06-20 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
JP2024512497A (ja) 2021-03-17 2024-03-19 武田薬品工業株式会社 血漿カリクレインの阻害剤
CN117396473A (zh) 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂
US20240199613A1 (en) 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
CN117396474A (zh) 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂
BR112023018619A2 (pt) 2021-03-17 2023-11-28 Takeda Pharmaceuticals Co Inibidores de heteroaril de calicreína plasmática

Similar Documents

Publication Publication Date Title
JP2021517893A5 (enExample)
US20260098036A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
AU2012245106B2 (en) Androgen receptor modulating carboxamides
JP5571073B2 (ja) S1p1受容体作働薬およびその使用
JP2020530446A5 (enExample)
CA2610888A1 (en) Inhibitors of akt activity
RU2012143794A (ru) Производные n-(имидазопиримидин-7-ил)-гетероаламидов и их применение в качестве ингибиторов pde10a
JP2014525444A5 (enExample)
JP2013523884A5 (enExample)
CN103987710A (zh) 新的*嗪衍生物及它们在治疗疾病中的应用
KR20180095904A (ko) 심혈관 질환을 치료하기 위한 cGMP 조정제로서의 4-아미노-2-(1H-피라졸로[3,4-B]피리딘-3-일)-6-옥소-6,7-디히드로-5H-피롤로[2,3-D]피리딘 유도체 및 각각의 (1H-인다졸-3-일) 유도체
SG185777A1 (en) Soluble guanylate cyclase activators
JP2010513283A (ja) 新規なオキサジアゾール化合物
EP3713922A1 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
JP2014505688A (ja) オキサジン誘導体および神経障害の処置におけるその使用
AU2017260125A1 (en) Aromatic sulfonamide derivatives
JP2017193592A5 (enExample)
JP2008523041A5 (enExample)
RU2011116230A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP6849618B2 (ja) 中性エンドペプチダーゼの阻害剤(NEP阻害剤)および/またはアンジオテンシンII拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ(sGC)の刺激薬および/または活性化薬ならびにその使用
RU2013136778A (ru) Ингибиторы гистондезацетилазы, композиции и способы их применения
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
JP2020526549A5 (enExample)
JP2009501775A5 (enExample)
JP2021535137A5 (enExample)